Literature DB >> 10698235

Cardiotoxicity of doxorubicin and other anthracycline derivatives.

D Jain1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10698235     DOI： 10.1067/mnc.2000.103324

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN： 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  75 in total

1.  Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer.

Authors:  M Estorch; I Carrió; L Berná; C Martínez-Duncker; C Alonso; J R Germá; B Ojeda
Journal:  J Nucl Med       Date:  1990-12       Impact factor: 10.057

2.  Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer.

Authors:  A M Goorin; A R Chauvenet; A R Perez-Atayde; J Cruz; R McKone; S E Lipshultz
Journal:  J Pediatr       Date:  1990-01       Impact factor: 4.406

3.  Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic.

Authors:  J Gehl; M Boesgaard; T Paaske; B Vittrup Jensen; P Dombernowsky
Journal:  Ann Oncol       Date:  1996-09       Impact factor: 32.976

Review 4.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

5.  Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe(III)-mitoxantrone complex.

Authors:  E H Herman; J Zhang; B B Hasinoff; J R Clark; V J Ferrans
Journal:  J Mol Cell Cardiol       Date:  1997-09       Impact factor: 5.000

6.  Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy.

Authors:  F M Torti; M M Bristow; B L Lum; S K Carter; A E Howes; D A Aston; B W Brown; J F Hannigan; F J Meyers; E P Mitchell
Journal:  Cancer Res       Date:  1986-07       Impact factor: 12.701

Review 7.  Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.

Authors:  M M Goldenberg
Journal:  Clin Ther       Date:  1999-02       Impact factor: 3.393

Review 8.  The anthracycline antineoplastic drugs.

Authors:  R C Young; R F Ozols; C E Myers
Journal:  N Engl J Med       Date:  1981-07-16       Impact factor: 91.245

9.  Potential cardiotoxicity with mitoxantrone.

Authors:  F C Schell; H Y Yap; G Blumenschein; M Valdivieso; G Bodey
Journal:  Cancer Treat Rep       Date:  1982-08

10.  Plasma endothelin-1 as a marker for doxorubicin cardiotoxicity.

Authors:  J Yamashita; M Ogawa; T Shirakusa
Journal:  Int J Cancer       Date:  1995-09-04       Impact factor: 7.396
View more
  26 in total

Review 1.  Pathophysiology of valvular heart disease: implications for nuclear imaging.

Authors:  Blasé Carabello
Journal:  J Nucl Cardiol       Date:  2002 Jan-Feb       Impact factor: 5.952

Review 2.  Apoptosis-detecting radioligands: current state of the art and future perspectives.

Authors:  Christophe M M Lahorte; Jean-Luc Vanderheyden; Neil Steinmetz; Christophe Van de Wiele; Rudi A Dierckx; Guido Slegers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-12       Impact factor: 9.236

Review 3.  Tumor-targeted drug delivery with aptamers.

Authors:  Y Zhang; H Hong; W Cai
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

4.  BN52021 protects rat cardiomyocyte from doxorubicin induced cardiotoxicity.

Authors:  Wen Yan; Chengluan Xuan; Lei Xuan; Rihao Xu; Junnan Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

5.  Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era.

Authors:  Isao Mitani; Diwakar Jain; Tammy M Joska; Barbara Burtness; Barry L Zaret
Journal:  J Nucl Cardiol       Date:  2003 Mar-Apr       Impact factor: 5.952

6.  Vitexin attenuates acute doxorubicin cardiotoxicity in rats via the suppression of oxidative stress, inflammation and apoptosis and the activation of FOXO3a.

Authors:  Zhan Sun; Bin Yan; Wen Yan Yu; Xueping Yao; Xiaojuan Ma; Geli Sheng; Qi Ma
Journal:  Exp Ther Med       Date:  2016-07-13       Impact factor: 2.447

7.  Amelioration of doxorubicin-induced cardiotoxicity by an anticancer-antioxidant dual-function compound, HO-3867.

Authors:  Alex Dayton; Karuppaiyah Selvendiran; Sarath Meduru; Mahmood Khan; M Lakshmi Kuppusamy; Shan Naidu; Tamás Kálai; Kálmán Hideg; Periannan Kuppusamy
Journal:  J Pharmacol Exp Ther       Date:  2011-07-28       Impact factor: 4.030

8.  Pharmacokinetic-pharmacodynamic modelling of acute N-terminal pro B-type natriuretic peptide after doxorubicin infusion in breast cancer.

Authors:  Shuang Liang; Richard C Brundage; Pamala A Jacobson; Anne Blaes; Mark N Kirstein
Journal:  Br J Clin Pharmacol       Date:  2016-06-03       Impact factor: 4.335

9.  Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance.

Authors:  Ayman Khdair; Di Chen; Yogesh Patil; Linan Ma; Q Ping Dou; Malathy P V Shekhar; Jayanth Panyam
Journal:  J Control Release       Date:  2009-09-11       Impact factor: 9.776

10.  Aldose reductase inhibitor, fidarestat prevents doxorubicin-induced endothelial cell death and dysfunction.

Authors:  Himangshu Sonowal; Pabitra Pal; Kirtikar Shukla; Ashish Saxena; Satish K Srivastava; Kota V Ramana
Journal:  Biochem Pharmacol       Date:  2018-02-16       Impact factor: 5.858
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.